{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:29:35Z","timestamp":1791214175309,"version":"4.1.0"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Biohaven Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine affects 1.1 billion people globally and is the second leading cause of disability worldwide. In clinical trials, treatment efficacy is evaluated by comparing the differential responses in the treatment and placebo arms. Although placebo response in preventive migraine trials has been studied, there is limited research examining temporal trends. This study evaluates the trend of placebo response over thirty years in migraine prevention trials and investigates the association of potential confounders, such as patient, treatment, and study characteristics on placebo response using meta-analysis with regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted literature searches from January 1990 to August 2021 in bibliographical databases (PubMed, Cochrane Library, and EMBASE). Studies were selected according to PICOS criteria and included randomized, double-blind, placebo-controlled trials evaluating preventive migraine treatments in adult patients diagnosed with episodic or chronic migraine, with or without aura. The protocol was registered with PROSPERO (CRD42021271732). Migraine efficacy outcomes included were either continuous (e.g., monthly migraine days) or dichotomous (e.g.,\u2009\u2265\u200950% responder rate (yes\/no)). We assessed the correlation of the change in outcome from baseline in the placebo arm, with the year of publication. The relationship between placebo response and year of publication was also assessed after accounting to confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 907 studies were identified, and 83 were found eligible. For the continuous outcomes, the change from baseline in mean placebo response showed an increase over the years (rho\u2009=\u20090.32,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006). The multivariable regression analysis also showed an overall increase in placebo response over the years. The correlation analysis of dichotomous responses showed no significant linear trend between publication year and mean placebo response (rho\u2009=\u20090.08,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.596). Placebo response also varied by route of administration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Placebo response increased over the past 30\u00a0years in migraine preventive trials. This phenomenon should be considered when designing clinical trials and conducting meta-analyses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-023-01587-0","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T09:02:39Z","timestamp":1684227759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression"],"prefix":"10.1186","volume":"24","author":[{"given":"Stewart J.","family":"Tepper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"L\u2019Italien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Tweedie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Lodaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dushon","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Pathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Antaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H.","family":"Nathanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"issue":"2","key":"1587_CR1","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1097\/j.pain.0000000000002275","volume":"163","author":"S Safiri","year":"2022","unstructured":"Safiri S, Pourfathi H, Eagan A, Mansournia MA, Khodayari MT, Sullman MJM, Kaufman J, Collins G, Dai H, Bragazzi NL, Kolahi AA (2022) Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain 163(2):e293\u2013e309. https:\/\/doi.org\/10.1097\/j.pain.0000000000002275","journal-title":"Pain"},{"issue":"1","key":"1587_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, on behalf of Lifting The Burden: the Global Campaign against H (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21(1):137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0","journal-title":"J Headache Pain"},{"key":"1587_CR3","unstructured":"GBD Results. Institute for Health Metrics and Evaluation. https:\/\/ghdx.healthdata.org\/gbd-results-tool?params=gbd-api-2019-permalink\/22d7fb91623a1231780139d1cf7a6e9a. Accessed 3 May 2022"},{"issue":"4\u20136","key":"1587_CR4","first-page":"39","volume":"17","author":"D Mohanty","year":"2020","unstructured":"Mohanty D, Lippmann S (2020) CGRP Inhibitors for Migraine. Innov Clin Neurosci 17(4\u20136):39\u201340","journal-title":"Innov Clin Neurosci"},{"issue":"Suppl 1","key":"1587_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10072-018-3406-2","volume":"39","author":"F Frediani","year":"2018","unstructured":"Frediani F (2018) The evolution of migraine therapy: a new concept of care. Neurol Sci 39(Suppl 1):1\u20132. https:\/\/doi.org\/10.1007\/s10072-018-3406-2","journal-title":"Neurol Sci"},{"issue":"1","key":"1587_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ncl.2020.09.001","volume":"39","author":"E Caronna","year":"2021","unstructured":"Caronna E, Starling AJ (2021) Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine. Neurol Clin 39(1):1\u201319","journal-title":"Neurol Clin"},{"key":"1587_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev.psych.59.113006.095941","volume":"59","author":"DD Price","year":"2008","unstructured":"Price DD, Finniss DG, Benedetti F (2008) A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol 59:565\u2013590","journal-title":"Annu Rev Psychol"},{"issue":"12","key":"1587_CR8","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1097\/j.pain.0000000000000333","volume":"156","author":"AH Tuttle","year":"2015","unstructured":"Tuttle AH, Tohyama S, Ramsay T, Kimmelman J, Schweinhardt P, Bennett GJ, Mogil JS (2015) Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain 156(12):2616\u20132626. https:\/\/doi.org\/10.1097\/j.pain.0000000000000333","journal-title":"Pain"},{"issue":"4","key":"1587_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1212\/01.WNL.0000275528.01263.6c","volume":"70","author":"J Katz","year":"2008","unstructured":"Katz J, Finnerup NB, Dworkin RH (2008) Clinical trial outcome in neuropathic pain: relationship to study characteristics. Neurology 70(4):263\u2013272. https:\/\/doi.org\/10.1212\/01.WNL.0000275528.01263.6c","journal-title":"Neurology"},{"key":"1587_CR10","doi-asserted-by":"publisher","unstructured":"Gopalakrishnan M, Zhu H, Farchione TR, Mathis M, Mehta M, Uppoor R, Younis I (2020) The Trend of Increasing Placebo Response and Decreasing Treatment Effect in Schizophrenia Trials Continues: An Update From the US Food and Drug Administration. J Clin Psychiatry 81 (2). https:\/\/doi.org\/10.4088\/JCP.19r12960","DOI":"10.4088\/JCP.19r12960"},{"issue":"9","key":"1587_CR11","doi-asserted-by":"publisher","first-page":"e2013196","DOI":"10.1001\/jamanetworkopen.2020.13196","volume":"3","author":"J Vollert","year":"2020","unstructured":"Vollert J, Cook NR, Kaptchuk TJ, Sehra ST, Tobias DK, Hall KT (2020) Assessment of Placebo Response in Objective and Subjective Outcome Measures in Rheumatoid Arthritis Clinical Trials. JAMA Netw Open 3(9):e2013196. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.13196","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1587_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1186\/s13063-016-1720-7","volume":"17","author":"KA Wartolowska","year":"2016","unstructured":"Wartolowska KA, Feakins BG, Collins GS, Cook J, Judge A, Rombach I, Dean BJF, Smith JA, Carr AJ (2016) The magnitude and temporal changes of response in the placebo arm of surgical randomized controlled trials: a systematic review and meta-analysis. Trials 17(1):589. https:\/\/doi.org\/10.1186\/s13063-016-1720-7","journal-title":"Trials"},{"issue":"2","key":"1587_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/0333102420960020","volume":"41","author":"K Evans","year":"2021","unstructured":"Evans K, Romero H, Spierings EL, Katz N (2021) The relation between the placebo response, observed treatment effect, and failure to meet primary endpoint: A systematic review of clinical trials of preventative pharmacological migraine treatments. Cephalalgia 41(2):247\u2013255. https:\/\/doi.org\/10.1177\/0333102420960020","journal-title":"Cephalalgia"},{"issue":"4","key":"1587_CR14","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1007\/s00415-019-09673-7","volume":"267","author":"L Kokoti","year":"2020","unstructured":"Kokoti L, Drellia K, Papadopoulos D, Mitsikostas DD (2020) Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis. J Neurol 267(4):1158\u20131170. https:\/\/doi.org\/10.1007\/s00415-019-09673-7","journal-title":"J Neurol"},{"issue":"21","key":"1587_CR15","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1001\/jamainternmed.2013.10391","volume":"173","author":"K Meissner","year":"2013","unstructured":"Meissner K, F\u00e4ssler M, R\u00fccker G, Kleijnen J, Hr\u00f3bjartsson A, Schneider A, Antes G, Linde K (2013) Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis. JAMA Intern Med 173(21):1941\u20131951. https:\/\/doi.org\/10.1001\/jamainternmed.2013.10391","journal-title":"JAMA Intern Med"},{"key":"1587_CR16","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition (2018). Cephalalgia 38 (1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"1587_CR17","doi-asserted-by":"publisher","unstructured":"The International Classification of Headache Disorders: 2nd edition (2004). Cephalalgia 24 Suppl 1:9\u2013160. https:\/\/doi.org\/10.1111\/j.1468-2982.2003.00824.x","DOI":"10.1111\/j.1468-2982.2003.00824.x"},{"issue":"Suppl 7","key":"1587_CR18","first-page":"1","volume":"8","author":"Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain","year":"1988","unstructured":"Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain (1988) Headache Classification Committee of the International Headache Society. Cephalalgia 8(Suppl 7):1\u201396","journal-title":"Cephalalgia"},{"key":"1587_CR19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"Bmj"},{"issue":"1","key":"1587_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312. https:\/\/doi.org\/10.1016\/0197-2456(95)00134-4","journal-title":"Control Clin Trials"},{"key":"1587_CR21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"1587_CR22","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. https:\/\/doi.org\/10.1136\/bmj.b2700","journal-title":"BMJ"},{"issue":"4","key":"1587_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.5808\/gi.2016.14.4.173","volume":"14","author":"CH Lee","year":"2016","unstructured":"Lee CH, Cook S, Lee JS, Han B (2016) Comparison of Two Meta-Analysis Methods: Inverse-Variance-Weighted Average and Weighted Sum of Z-Scores. Genomics Inform 14(4):173\u2013180. https:\/\/doi.org\/10.5808\/gi.2016.14.4.173","journal-title":"Genomics Inform"},{"key":"1587_CR24","doi-asserted-by":"publisher","unstructured":"Harrell F (2015) Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. https:\/\/doi.org\/10.1007\/978-3-319-19425-7","DOI":"10.1007\/978-3-319-19425-7"},{"issue":"4","key":"1587_CR25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1526-4610.2006.00624.x","volume":"47","author":"SK Aurora","year":"2007","unstructured":"Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM (2007) Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 47(4):486\u2013499. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00624.x","journal-title":"Headache"},{"issue":"4","key":"1587_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/rnn-160704","volume":"35","author":"M Ebrahimi-Monfared","year":"2017","unstructured":"Ebrahimi-Monfared M, Sharafkhah M, Abdolrazaghnejad A, Mohammadbeigi A, Faraji F (2017) Use of melatonin versus valproic acid in prophylaxis of migraine patients: A double-blind randomized clinical trial. Restor Neurol Neurosci 35(4):385\u2013393. https:\/\/doi.org\/10.3233\/rnn-160704","journal-title":"Restor Neurol Neurosci"},{"issue":"6","key":"1587_CR27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1468-2982.2007.01315.x","volume":"27","author":"M Relja","year":"2007","unstructured":"Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C (2007) A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 27(6):492\u2013503. https:\/\/doi.org\/10.1111\/j.1468-2982.2007.01315.x","journal-title":"Cephalalgia"},{"issue":"12","key":"1587_CR28","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.clinthera.2020.11.007","volume":"42","author":"TR Smith","year":"2020","unstructured":"Smith TR, Janelidze M, Chakhava G, Cady R, Hirman J, Allan B, Pederson S, Smith J, Schaeffler B (2020) Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study. Clin Ther 42(12):2254-2265.e2253. https:\/\/doi.org\/10.1016\/j.clinthera.2020.11.007","journal-title":"Clin Ther"},{"issue":"2","key":"1587_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1526-4610.2007.00963.x","volume":"48","author":"FG Freitag","year":"2008","unstructured":"Freitag FG, Diamond S, Diamond M, Urban G (2008) Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. Headache 48(2):201\u2013209. https:\/\/doi.org\/10.1111\/j.1526-4610.2007.00963.x","journal-title":"Headache"},{"issue":"5","key":"1587_CR30","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1046\/j.1468-2982.1998.1805283.x","volume":"18","author":"TJ Steiner","year":"1998","unstructured":"Steiner TJ, Ahmed F, Findley LJ, MacGregor EA, Wilkinson M (1998) S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia 18(5):283\u2013286. https:\/\/doi.org\/10.1046\/j.1468-2982.1998.1805283.x","journal-title":"Cephalalgia"},{"issue":"12","key":"1587_CR31","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1177\/0333102410370875","volume":"30","author":"HO H\u00f8ivik","year":"2010","unstructured":"H\u00f8ivik HO, Laurijssens BE, Harnisch LO, Twomey CK, Dixon RM, Kirkham AJ, Williams PM, Wentz AL, Lunnon MW (2010) Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 30(12):1458\u20131467. https:\/\/doi.org\/10.1177\/0333102410370875","journal-title":"Cephalalgia"},{"issue":"2","key":"1587_CR32","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1526-4610.2005.05029.x","volume":"45","author":"SN Ozyalcin","year":"2005","unstructured":"Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R (2005) The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 45(2):144\u2013152. https:\/\/doi.org\/10.1111\/j.1526-4610.2005.05029.x","journal-title":"Headache"},{"issue":"1","key":"1587_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5(1):13. https:\/\/doi.org\/10.1186\/1471-2288-5-13","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"1587_CR34","doi-asserted-by":"publisher","first-page":"874","DOI":"10.2174\/1871530319666190212170140","volume":"19","author":"M Abdolahi","year":"2019","unstructured":"Abdolahi M, Jafarieh A, Sarraf P, Sedighiyan M, Yousefi A, Tafakhori A, Abdollahi H, Salehinia F, Djalali M (2019) The Neuromodulatory Effects of \u03c9-3 Fatty Acids and Nano-Curcumin on the COX-2\/ iNOS Network in Migraines: A Clinical Trial Study from Gene Expression to Clinical Symptoms. Endocr Metab Immune Disord Drug Targets 19(6):874\u2013884. https:\/\/doi.org\/10.2174\/1871530319666190212170140","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"3","key":"1587_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/01.mjt.0000212705.79248.74","volume":"13","author":"KS Anand","year":"2006","unstructured":"Anand KS, Prasad A, Singh MM, Sharma S, Bala K (2006) Botulinum toxin type A in prophylactic treatment of migraine. Am J Ther 13(3):183\u2013187. https:\/\/doi.org\/10.1097\/01.mjt.0000212705.79248.74","journal-title":"Am J Ther"},{"issue":"3","key":"1587_CR36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Smith J (2020) Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241\u2013254. https:\/\/doi.org\/10.1177\/0333102420905132","journal-title":"Cephalalgia"},{"issue":"7","key":"1587_CR37","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30(7):793\u2013803. https:\/\/doi.org\/10.1177\/0333102410364676","journal-title":"Cephalalgia"},{"issue":"3","key":"1587_CR38","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s10194-003-0049-2","volume":"4","author":"N Barrientos","year":"2003","unstructured":"Barrientos N, Chana P (2003) Botulinum toxin type A in prophylactic treatment of migraine headaches: A preliminary study. J Headache Pain 4(3):146\u2013151. https:\/\/doi.org\/10.1007\/s10194-003-0049-2","journal-title":"J Headache Pain"},{"issue":"11","key":"1587_CR39","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(15)00245-8","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings ELH, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14(11):1091\u20131100. https:\/\/doi.org\/10.1016\/S1474-4422(15)00245-8","journal-title":"Lancet Neurol"},{"issue":"11","key":"1587_CR40","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/s1474-4422(15)00249-5","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14(11):1081\u20131090. https:\/\/doi.org\/10.1016\/s1474-4422(15)00249-5","journal-title":"Lancet Neurol"},{"issue":"6","key":"1587_CR41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1526-4610.2004.446006.x","volume":"44","author":"JL Brandes","year":"2004","unstructured":"Brandes JL, Visser WH, Farmer MV, Schuhl AL, Malbecq W, Vrijens F, Lines CR, Reines SA (2004) Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study. Headache 44(6):581\u2013586. https:\/\/doi.org\/10.1111\/j.1526-4610.2004.446006.x","journal-title":"Headache"},{"issue":"6","key":"1587_CR42","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/ana.24534","volume":"78","author":"C Buettner","year":"2015","unstructured":"Buettner C, Nir RR, Bertisch SM, Bernstein C, Schain A, Mittleman MA, Burstein R (2015) Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial. Ann Neurol 78(6):970\u2013981. https:\/\/doi.org\/10.1002\/ana.24534","journal-title":"Ann Neurol"},{"issue":"2","key":"1587_CR43","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.1526-4610.2008.01326.x","volume":"49","author":"RK Cady","year":"2009","unstructured":"Cady RK, Mathew N, Diener HC, Hu P, Haas M, Novak GP (2009) Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache 49(2):216\u2013226. https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01326.x","journal-title":"Headache"},{"issue":"1","key":"1587_CR44","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.clnu.2018.01.013","volume":"38","author":"J Izquierdo-Casas","year":"2019","unstructured":"Izquierdo-Casas J, Comas-Bast\u00e9 O, Latorre-Moratalla ML, Lorente-Gasc\u00f3n M, Duelo A, Soler-Singla L, Vidal-Carou MC (2019) Diamine oxidase (DAO) supplement reduces headache in episodic migraine patients with DAO deficiency: A randomized double-blind trial. Clin Nutr 38(1):152\u2013158. https:\/\/doi.org\/10.1016\/j.clnu.2018.01.013","journal-title":"Clin Nutr"},{"issue":"1","key":"1587_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1526-4610.2010.01807.x","volume":"51","author":"S Chankrachang","year":"2011","unstructured":"Chankrachang S, Arayawichanont A, Poungvarin N, Nidhinandana S, Boonkongchuen P, Towanabut S, Sithinamsuwan P, Kongsaengdao S (2011) Prophylactic botulinum type A toxin complex (Dysport\u00ae) for migraine without aura. Headache 51(1):52\u201363. https:\/\/doi.org\/10.1111\/j.1526-4610.2010.01807.x","journal-title":"Headache"},{"issue":"10268","key":"1587_CR46","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ (2021) Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet 397(10268):51\u201360. https:\/\/doi.org\/10.1016\/s0140-6736(20)32544-7","journal-title":"Lancet"},{"issue":"24","key":"1587_CR47","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/wnl.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211\u2013e2221. https:\/\/doi.org\/10.1212\/wnl.0000000000006640","journal-title":"Neurology"},{"issue":"1","key":"1587_CR48","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1046\/j.1468-2982.2001.00153.x","volume":"21","author":"HC Diener","year":"2001","unstructured":"Diener HC, Krupp P, Schmitt T, Steitz G, Milde K, Freytag S (2001) Cyclandelate in the prophylaxis of migraine: a placebo-controlled study. Cephalalgia 21(1):66\u201370. https:\/\/doi.org\/10.1046\/j.1468-2982.2001.00153.x","journal-title":"Cephalalgia"},{"issue":"11","key":"1587_CR49","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/j.1468-2982.2005.00950.x","volume":"25","author":"HC Diener","year":"2005","unstructured":"Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-Von Zepelin HH (2005) Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention - A randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 25(11):1031\u20131041. https:\/\/doi.org\/10.1111\/j.1468-2982.2005.00950.x","journal-title":"Cephalalgia"},{"issue":"9","key":"1587_CR50","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1468-2982.2008.01825.x","volume":"29","author":"HC Diener","year":"2008","unstructured":"Diener HC, Gendolla A, Feuersenger A, Evers S, Straube A, Schumacher H, Davidai G (2008) Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia 29(9):921\u2013927. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01825.x","journal-title":"Cephalalgia"},{"issue":"7","key":"1587_CR51","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7):804\u2013814. https:\/\/doi.org\/10.1177\/0333102410364677","journal-title":"Cephalalgia"},{"issue":"7","key":"1587_CR52","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","volume":"27","author":"HC Diener","year":"2007","unstructured":"Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27(7):814\u2013823. https:\/\/doi.org\/10.1111\/j.1468-2982.2007.01326.x","journal-title":"Cephalalgia"},{"issue":"6","key":"1587_CR53","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1468-2982.1996.1606441.x","volume":"16","author":"HC Diener","year":"1996","unstructured":"Diener HC, F\u00f6h M, Iaccarino C, Wessely P, Isler H, Strenge H, Fischer M, Wedekind W, Taneri Z (1996) Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. The Study group. Cephalalgia 16(6):441\u2013447. https:\/\/doi.org\/10.1046\/j.1468-2982.1996.1606441.x","journal-title":"Cephalalgia"},{"issue":"19","key":"1587_CR54","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E (2018) Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA 319(19):1999\u20132008. https:\/\/doi.org\/10.1001\/jama.2018.4853","journal-title":"JAMA"},{"issue":"11","key":"1587_CR55","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Gerson W, Jagadeesan S, Marcadis I, Maynard J, Saper J, Vatakis N, Winkle P, Patrick K, Daniels S, Haase G, Strout C, Nieto R, Krause R, Omidvar O, Spierings E, Goldstein J, Cady R, Davis M, Chuck L, Backonja M, Koltun W (2014) Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: A randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13(11):1100\u20131107. https:\/\/doi.org\/10.1016\/S1474-4422(14)70209-1","journal-title":"Lancet Neurol"},{"issue":"6","key":"1587_CR56","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA (2018) ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38(6):1026\u20131037. https:\/\/doi.org\/10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"issue":"9","key":"1587_CR57","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1474-4422(14)70128-0","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Spierings ELH, Scherer JC, Sweeney SP, Grayzel DS (2014) Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13(9):885\u2013892. https:\/\/doi.org\/10.1016\/S1474-4422(14)70128-0","journal-title":"Lancet Neurol"},{"issue":"9","key":"1587_CR58","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1177\/0333102419858355","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J (2019) Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia 39(9):1075\u20131085. https:\/\/doi.org\/10.1177\/0333102419858355","journal-title":"Cephalalgia"},{"key":"1587_CR59","doi-asserted-by":"publisher","unstructured":"Elkind AH, O\u2019Carroll P, Blumenfeld A, DeGryse R, Dimitrova R (2006) A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 7(10):688\u2013696. https:\/\/doi.org\/10.1016\/j.jpain.2006.03.002","DOI":"10.1016\/j.jpain.2006.03.002"},{"issue":"10","key":"1587_CR60","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1468-2982.2004.00754.x","volume":"24","author":"S Evers","year":"2004","unstructured":"Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A (2004) Botulinum toxin A in the prophylactic treatment of migraine - A randomized, double-blind, placebo-controlled study. Cephalalgia 24(10):838\u2013843. https:\/\/doi.org\/10.1111\/j.1468-2982.2004.00754.x","journal-title":"Cephalalgia"},{"issue":"10203","key":"1587_CR61","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, Mueller M, Ahn AH, Schwartz YC, Grozinski-Wolff M et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394(10203):1030\u20131040. https:\/\/doi.org\/10.1016\/S0140-6736(19)31946-4","journal-title":"Lancet"},{"key":"1587_CR62","doi-asserted-by":"publisher","unstructured":"Fu C, Yu L, Zou Y, Cao K, Zhao J, Gong H, Zhang S, Lin A, Dong M, Yang W, Li T, He L, Su F, Wu R, Lin D (2012) Efficacy of Chuanxiong Ding Tong herbal formula granule in the treatment and prophylactic of migraine patients: A randomized, double-blind, multicenter, placebo-controlled trial. Evidence-based Complementary and Alternative Medicine 2012. https:\/\/doi.org\/10.1155\/2012\/967968","DOI":"10.1155\/2012\/967968"},{"key":"1587_CR63","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s10194-015-0516-6","volume":"16","author":"C Gaul","year":"2015","unstructured":"Gaul C, Diener HC, Danesch U (2015) Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain 16:516. https:\/\/doi.org\/10.1186\/s10194-015-0516-6","journal-title":"J Headache Pain"},{"issue":"22","key":"1587_CR64","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA (2017) A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 377(22):2123\u20132132. https:\/\/doi.org\/10.1056\/NEJMoa1705848","journal-title":"N Engl J Med"},{"issue":"7","key":"1587_CR65","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/j.1468-2982.2008.01804.x","volume":"29","author":"PJ Goadsby","year":"2009","unstructured":"Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG (2009) Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 29(7):742\u2013750. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01804.x","journal-title":"Cephalalgia"},{"issue":"9","key":"1587_CR66","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/s1474-4422(20)30234-9","volume":"19","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A (2020) Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol 19(9):727\u2013737. https:\/\/doi.org\/10.1016\/s1474-4422(20)30234-9","journal-title":"Lancet Neurol"},{"issue":"10","key":"1587_CR67","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1136\/jnnp-2016-313458","volume":"87","author":"AL Gon\u00e7alves","year":"2016","unstructured":"Gon\u00e7alves AL, Martini Ferreira A, Ribeiro RT, Zukerman E, Cipolla-Neto J, Peres MF (2016) Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry 87(10):1127\u20131132. https:\/\/doi.org\/10.1136\/jnnp-2016-313458","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"1587_CR68","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1177\/0333102418821661","volume":"39","author":"P Hajihashemi","year":"2019","unstructured":"Hajihashemi P, Askari G, Khorvash F, Reza Maracy M, Nourian M (2019) The effects of concurrent Coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial. Cephalalgia 39(5):648\u2013654. https:\/\/doi.org\/10.1177\/0333102418821661","journal-title":"Cephalalgia"},{"issue":"9","key":"1587_CR69","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/ajp.0000000000000739","volume":"35","author":"LB Kisler","year":"2019","unstructured":"Kisler LB, Weissman-Fogel I, Coghill RC, Sprecher E, Yarnitsky D, Granovsky Y (2019) Individualization of Migraine Prevention: A Randomized Controlled Trial of Psychophysical-based Prediction of Duloxetine Efficacy. Clin J Pain 35(9):753\u2013765. https:\/\/doi.org\/10.1097\/ajp.0000000000000739","journal-title":"Clin J Pain"},{"issue":"2","key":"1587_CR70","first-page":"101","volume":"21","author":"E K\u00f6seoglu","year":"2008","unstructured":"K\u00f6seoglu E, Talaslioglu A, G\u00f6n\u00fcl AS, Kula M (2008) The effects of magnesium prophylaxis in migraine without aura. Magnes Res 21(2):101\u2013108","journal-title":"Magnes Res"},{"issue":"1","key":"1587_CR71","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/0333102410372427","volume":"31","author":"RB Lipton","year":"2011","unstructured":"Lipton RB, Silberstein S, Dodick D, Cady R, Freitag F, Mathew N, Biondi DM, Ascher S, Olson WH, Hulihan J (2011) Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia 31(1):18\u201330. https:\/\/doi.org\/10.1177\/0333102410372427","journal-title":"Cephalalgia"},{"issue":"13","key":"1587_CR72","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/wnl.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Cady R (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365\u2013e1377. https:\/\/doi.org\/10.1212\/wnl.0000000000009169","journal-title":"Neurology"},{"issue":"12","key":"1587_CR73","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1212\/01.wnl.0000147290.68260.11","volume":"63","author":"RB Lipton","year":"2004","unstructured":"Lipton RB, G\u00f6bel H, Einh\u00e4upl KM, Wilks K, Mauskop A (2004) Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 63(12):2240\u20132244. https:\/\/doi.org\/10.1212\/01.wnl.0000147290.68260.11","journal-title":"Neurology"},{"issue":"1","key":"1587_CR74","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1526-4610.2006.00626.x","volume":"47","author":"D Magis","year":"2007","unstructured":"Magis D, Ambrosini A, S\u00e1ndor P, Jacquy J, Laloux P, Schoenen J (2007) A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache 47(1):52\u201357. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00626.x","journal-title":"Headache"},{"issue":"5","key":"1587_CR75","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10072-004-0350-0","volume":"25","author":"D Mei","year":"2004","unstructured":"Mei D, Capuano A, Vollono C, Evangelista M, Ferraro D, Tonali P, Di Trapani G (2004) Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurol Sci 25(5):245\u2013250. https:\/\/doi.org\/10.1007\/s10072-004-0350-0","journal-title":"Neurol Sci"},{"issue":"2","key":"1587_CR76","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1017\/s0317167100004960","volume":"33","author":"RO Mill\u00e1n-Guerrero","year":"2006","unstructured":"Mill\u00e1n-Guerrero RO, Isais-Mill\u00e1n R, Benjam\u00edn TH, Tene CE (2006) Nalpha-methyl histamine safety and efficacy in migraine prophylaxis: phase III study. Can J Neurol Sci 33(2):195\u2013199. https:\/\/doi.org\/10.1017\/s0317167100004960","journal-title":"Can J Neurol Sci"},{"issue":"10","key":"1587_CR77","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/s1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19(10):814\u2013825. https:\/\/doi.org\/10.1016\/s1474-4422(20)30279-9","journal-title":"Lancet Neurol"},{"issue":"1","key":"1587_CR78","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/head.12732","volume":"56","author":"R Noruzzadeh","year":"2016","unstructured":"Noruzzadeh R, Modabbernia A, Aghamollaii V, Ghaffarpour M, Harirchian MH, Salahi S, Nikbakht N, Noruzi N, Tafakhori A (2016) Memantine for Prophylactic Treatment of Migraine Without Aura: A Randomized Double-Blind Placebo-Controlled Study. Headache 56(1):95\u2013103. https:\/\/doi.org\/10.1111\/head.12732","journal-title":"Headache"},{"issue":"4","key":"1587_CR79","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1046\/j.1468-2982.1996.1604257.x","volume":"16","author":"A Peikert","year":"1996","unstructured":"Peikert A, Wilimzig C, K\u00f6hne-Volland R (1996) Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 16(4):257\u2013263. https:\/\/doi.org\/10.1046\/j.1468-2982.1996.1604257.x","journal-title":"Cephalalgia"},{"issue":"4","key":"1587_CR80","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000228987","volume":"62","author":"S Petri","year":"2009","unstructured":"Petri S, T\u00f6lle T, Straube A, Pfaffenrath V, Stefenelli U, Ceballos-Baumann A (2009) Botulinum toxin as preventive treatment for migraine: a randomized double-blind study. Eur Neurol 62(4):204\u2013211. https:\/\/doi.org\/10.1159\/000228987","journal-title":"Eur Neurol"},{"issue":"7","key":"1587_CR81","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1046\/j.1468-2982.2002.00396.x","volume":"22","author":"V Pfaffenrath","year":"2002","unstructured":"Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-Von Zepelin HH (2002) The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis - A double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 22(7):523\u2013532. https:\/\/doi.org\/10.1046\/j.1468-2982.2002.00396.x","journal-title":"Cephalalgia"},{"issue":"6","key":"1587_CR82","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1046\/j.1468-2982.1996.1606436.x","volume":"16","author":"V Pfaffenrath","year":"1996","unstructured":"Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH, Taneri Z, Soyka D, G\u00f6bel H, Fischer M (1996) Magnesium in the prophylaxis of migraine - A double-blind, placebo-controlled study. Cephalalgia 16(6):436\u2013440. https:\/\/doi.org\/10.1046\/j.1468-2982.1996.1606436.x","journal-title":"Cephalalgia"},{"issue":"8","key":"1587_CR83","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1046\/j.1468-2982.2001.218240.x","volume":"21","author":"A Pradalier","year":"2001","unstructured":"Pradalier A, Bakouche P, Baudesson G, Delage A, Cornaille-Lafage G, Launay JM, Biason P (2001) Failure of omega-3 polyunsaturated fatty acids in prevention of migraine: a double-blind study versus placebo. Cephalalgia 21(8):818\u2013822. https:\/\/doi.org\/10.1046\/j.1468-2982.2001.218240.x","journal-title":"Cephalalgia"},{"issue":"10161","key":"1587_CR84","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/s0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392(10161):2280\u20132287. https:\/\/doi.org\/10.1016\/s0140-6736(18)32534-0","journal-title":"Lancet"},{"issue":"1","key":"1587_CR85","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/0972-2327.144290","volume":"18","author":"H Sadeghian","year":"2015","unstructured":"Sadeghian H, Motiei-Langroudi R (2015) Comparison of Levetiracetam and sodium Valproate in migraine prophylaxis: A randomized placebo-controlled study. Ann Indian Acad Neurol 18(1):45\u201348. https:\/\/doi.org\/10.4103\/0972-2327.144290","journal-title":"Ann Indian Acad Neurol"},{"key":"1587_CR86","doi-asserted-by":"publisher","unstructured":"Sakai F, Ozeki A, Skljarevski V (2020) Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial. Cephalalgia Reports 3. https:\/\/doi.org\/10.1177\/2515816320932573","DOI":"10.1177\/2515816320932573"},{"issue":"7","key":"1587_CR87","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/head.14169","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, Igarashi H, Hirata K, Takeshima T, Ning X, Shima T, Ishida M, Iba K, Kondo H, Koga N (2021) Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61(7):1092\u20131101. https:\/\/doi.org\/10.1111\/head.14169","journal-title":"Headache"},{"issue":"7","key":"1587_CR88","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/head.14178","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, Tatsuoka Y, Imai N, Ning X, Ishida M, Nagano K, Iba K, Kondo H, Koga N (2021) Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61(7):1102\u20131111. https:\/\/doi.org\/10.1111\/head.14178","journal-title":"Headache"},{"issue":"10","key":"1587_CR89","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1111\/head.13652","volume":"59","author":"F Sakai","year":"2019","unstructured":"Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Lenz R, Wang Y, Cheng S, Hirama T, Mikol DD (2019) A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults. Headache 59(10):1731\u20131742. https:\/\/doi.org\/10.1111\/head.13652","journal-title":"Headache"},{"issue":"4","key":"1587_CR90","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1212\/01.Wnl.0000151975.03598.Ed","volume":"64","author":"PS S\u00e1ndor","year":"2005","unstructured":"S\u00e1ndor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel L, Agosti RM, Schoenen J (2005) Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 64(4):713\u2013715. https:\/\/doi.org\/10.1212\/01.Wnl.0000151975.03598.Ed","journal-title":"Neurology"},{"issue":"2","key":"1587_CR91","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1212\/wnl.50.2.466","volume":"50","author":"J Schoenen","year":"1998","unstructured":"Schoenen J, Jacquy J, Lenaerts M (1998) Effectiveness of high-dose riboflavin in migraine prophylaxis A randomized controlled trial. Neurology 50(2):466\u2013470. https:\/\/doi.org\/10.1212\/wnl.50.2.466","journal-title":"Neurology"},{"key":"1587_CR92","doi-asserted-by":"publisher","unstructured":"Silberstein S, Diamond M, Hindiyeh NA, Biondi DM, Cady R, Hirman J, Allan B, Pederson S, Schaeffler B, Smith J (2020) Eptinezumab for the prevention of chronic migraine: Efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. Journal of Headache and Pain 21 (1). https:\/\/doi.org\/10.1186\/s10194-020-01186-3","DOI":"10.1186\/s10194-020-01186-3"},{"issue":"2","key":"1587_CR93","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","volume":"47","author":"SD Silberstein","year":"2007","unstructured":"Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S et al (2007) Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47(2):170\u2013180. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00684.x","journal-title":"Headache"},{"issue":"7","key":"1587_CR94","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.clinthera.2006.07.003","volume":"28","author":"SD Silberstein","year":"2006","unstructured":"Silberstein SD, Hulihan J, Karim MR, Wu SC, Jordan D, Karvois D, Kamin M (2006) Efficacy and tolerability of topiramate 200 mg\/d in the prevention of migraine with\/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther 28(7):1002\u20131011. https:\/\/doi.org\/10.1016\/j.clinthera.2006.07.003","journal-title":"Clin Ther"},{"issue":"22","key":"1587_CR95","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E (2017) Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med 377(22):2113\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa1709038","journal-title":"N Engl J Med"},{"issue":"1","key":"1587_CR96","first-page":"47","volume":"13","author":"M Siniatchkin","year":"1998","unstructured":"Siniatchkin M, Gerber WD, Vein A (1998) Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study. Funct Neurol 13(1):47\u201356","journal-title":"Funct Neurol"},{"issue":"9","key":"1587_CR97","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/j.1468-2982.2007.01377.x","volume":"27","author":"M Siniatchkin","year":"2007","unstructured":"Siniatchkin M, Andrasik F, Kropp P, Niederberger U, Strenge H, Averkina N, Lindner V, Stephani U, Gerber WD (2007) Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo-controlled study. Cephalalgia 27(9):1024\u20131032. https:\/\/doi.org\/10.1111\/j.1468-2982.2007.01377.x","journal-title":"Cephalalgia"},{"issue":"2","key":"1587_CR98","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamaneurol.2017.3859","volume":"75","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A, Goadsby PJ, Dodick DW (2018) Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial. JAMA Neurol 75(2):187\u2013193. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3859","journal-title":"JAMA Neurol"},{"issue":"8","key":"1587_CR99","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442\u20131454. https:\/\/doi.org\/10.1177\/0333102418779543","journal-title":"Cephalalgia"},{"issue":"9","key":"1587_CR100","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol 75(9):1080\u20131088. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1212","journal-title":"JAMA Neurol"},{"issue":"10","key":"1587_CR101","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1046\/j.1526-4610.2001.01190.x","volume":"41","author":"JR Storey","year":"2001","unstructured":"Storey JR, Calder CS, Hart DE, Potter DL (2001) Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 41(10):968\u2013975. https:\/\/doi.org\/10.1046\/j.1526-4610.2001.01190.x","journal-title":"Headache"},{"issue":"4","key":"1587_CR102","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/s1474-4422(16)00019-3","volume":"15","author":"H Sun","year":"2016","unstructured":"Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15(4):382\u2013390. https:\/\/doi.org\/10.1016\/s1474-4422(16)00019-3","journal-title":"Lancet Neurol"},{"issue":"6","key":"1587_CR103","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/head.14138","volume":"61","author":"T Takeshima","year":"2021","unstructured":"Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD (2021) Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study. Headache 61(6):927\u2013935. https:\/\/doi.org\/10.1111\/head.14138","journal-title":"Headache"},{"issue":"6","key":"1587_CR104","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/s1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425\u2013434. https:\/\/doi.org\/10.1016\/s1474-4422(17)30083-2","journal-title":"Lancet Neurol"},{"issue":"3","key":"1587_CR105","first-page":"145","volume":"151","author":"G Di Trapani","year":"2000","unstructured":"Di Trapani G, Mei D, Marra C, Mazza S, Capuano A (2000) Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ter 151(3):145\u2013148","journal-title":"Clin Ter"},{"issue":"2","key":"1587_CR106","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/pl00007866","volume":"249","author":"K Vahedi","year":"2002","unstructured":"Vahedi K, Taupin P, Djomby R, El-Amrani M, Lutz G, Filipetti V, Landais P, Massiou H, Bousser MG (2002) Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomised placebo-controlled trial. J Neurol 249(2):206\u2013211. https:\/\/doi.org\/10.1007\/pl00007866","journal-title":"J Neurol"},{"key":"1587_CR107","doi-asserted-by":"publisher","unstructured":"Wang SJ, Roxas AA, Jr., Saravia B, Kim BK, Chowdhury D, Riachi N, Tai MS, Tanprawate S, Ngoc TT, Zhao YJ, Mikol DD, Pandhi S, Wen S, Mondal S, Tenenbaum N, Hours-Zesiger P (2021) Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study. Cephalalgia:3331024211024160. https:\/\/doi.org\/10.1177\/03331024211024160","DOI":"10.1177\/03331024211024160"},{"key":"1587_CR108","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002365","author":"DB Swerts","year":"2021","unstructured":"Swerts DB, Benedetti F, Peres MFP (2021) Different routes of administration in chronic migraine prevention lead to different placebo responses: a meta-analysis. Pain. https:\/\/doi.org\/10.1097\/j.pain.0000000000002365","journal-title":"Pain"},{"issue":"3","key":"1587_CR109","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s004150050560","volume":"247","author":"AJ de Craen","year":"2000","unstructured":"de Craen AJ, Tijssen JG, de Gans J, Kleijnen J (2000) Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. J Neurol 247(3):183\u2013188. https:\/\/doi.org\/10.1007\/s004150050560","journal-title":"J Neurol"},{"issue":"4","key":"1587_CR110","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000490354","volume":"87","author":"AWM Evers","year":"2018","unstructured":"Evers AWM, Colloca L, Blease C, Annoni M, Atlas LY, Benedetti F, Bingel U, B\u00fcchel C, Carvalho C, Colagiuri B, Crum AJ, Enck P, Gaab J, Geers AL, Howick J, Jensen KB, Kirsch I, Meissner K, Napadow V, Peerdeman KJ, Raz A, Rief W, Vase L, Wager TD, Wampold BE, Weimer K, Wiech K, Kaptchuk TJ, Klinger R, Kelley JM (2018) Implications of Placebo and Nocebo Effects for Clinical Practice: Expert Consensus. Psychother Psychosom 87(4):204\u2013210. https:\/\/doi.org\/10.1159\/000490354","journal-title":"Psychother Psychosom"},{"key":"1587_CR111","doi-asserted-by":"publisher","unstructured":"Schwartz NA, Turturro MA, Istvan DJ, Larkin GL (2000) Patients\u2019 perceptions of route of nonsteroidal anti-inflammatory drug administration and its effect on analgesia. Acad Emerg Med 7(8):857\u2013861. https:\/\/doi.org\/10.1111\/j.1553-2712.2000.tb02061.x","DOI":"10.1111\/j.1553-2712.2000.tb02061.x"},{"issue":"9","key":"1587_CR112","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.joca.2013.04.018","volume":"21","author":"A Abhishek","year":"2013","unstructured":"Abhishek A, Doherty M (2013) Mechanisms of the placebo response in pain in osteoarthritis. Osteoarthritis Cartilage 21(9):1229\u20131235. https:\/\/doi.org\/10.1016\/j.joca.2013.04.018","journal-title":"Osteoarthritis Cartilage"},{"key":"1587_CR113","doi-asserted-by":"publisher","unstructured":"Doherty M, Dieppe P (2009) The \u201cplacebo\u201d response in osteoarthritis and its implications for clinical practice. Osteoarthritis Cartilage 17(10):1255\u20131262. https:\/\/doi.org\/10.1016\/j.joca.2009.03.023","DOI":"10.1016\/j.joca.2009.03.023"},{"issue":"4","key":"1587_CR114","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1037\/bul0000015","volume":"141","author":"TJ Johnsen","year":"2015","unstructured":"Johnsen TJ, Friborg O (2015) The effects of cognitive behavioral therapy as an anti-depressive treatment is falling: A meta-analysis. Psychol Bull 141(4):747\u2013768. https:\/\/doi.org\/10.1037\/bul0000015","journal-title":"Psychol Bull"},{"issue":"8","key":"1587_CR115","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/head.13907","volume":"60","author":"RB Forbes","year":"2020","unstructured":"Forbes RB, McCarron M, Cardwell CR (2020) Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta-analysis. Headache 60(8):1542\u20131557. https:\/\/doi.org\/10.1111\/head.13907","journal-title":"Headache"},{"issue":"3","key":"1587_CR116","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/wps.20245","volume":"14","author":"S Kasper","year":"2015","unstructured":"Kasper S, Dold M (2015) Factors contributing to the increasing placebo response in antidepressant trials. World Psychiatry 14(3):304\u2013306. https:\/\/doi.org\/10.1002\/wps.20245","journal-title":"World Psychiatry"},{"issue":"1572","key":"1587_CR117","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1098\/rstb.2010.0384","volume":"366","author":"P Enck","year":"2011","unstructured":"Enck P, Klosterhalfen S, Weimer K, Horing B, Zipfel S (2011) The placebo response in clinical trials: more questions than answers. Philos Trans R Soc Lond B Biol Sci 366(1572):1889\u20131895. https:\/\/doi.org\/10.1098\/rstb.2010.0384","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"4","key":"1587_CR118","doi-asserted-by":"publisher","first-page":"e202907","DOI":"10.1001\/jamanetworkopen.2020.2907","volume":"3","author":"AE Sanders","year":"2020","unstructured":"Sanders AE, Slade GD, Fillingim RB, Ohrbach R, Arbes SJ Jr, Tchivileva IE (2020) Effect of Treatment Expectation on Placebo Response and Analgesic Efficacy: A Secondary Aim in a Randomized Clinical Trial. JAMA Netw Open 3(4):e202907\u2013e202907. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.2907","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1587_CR119","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s10194-021-01366-9","volume":"22","author":"A Alpuente","year":"2021","unstructured":"Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrus M, Pozo-Rosich P (2021) In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study. J Headache Pain 22(1):151. https:\/\/doi.org\/10.1186\/s10194-021-01366-9","journal-title":"J Headache Pain"},{"issue":"5","key":"1587_CR120","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ (2018) Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 38(5):815\u2013832. https:\/\/doi.org\/10.1177\/0333102418758283","journal-title":"Cephalalgia"},{"key":"1587_CR121","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/164_2019_269","volume":"260","author":"P Enck","year":"2019","unstructured":"Enck P, Klosterhalfen S (2019) Placebos and the Placebo Effect in Drug Trials. Handb Exp Pharmacol 260:399\u2013431. https:\/\/doi.org\/10.1007\/164_2019_269","journal-title":"Handb Exp Pharmacol"},{"issue":"9","key":"1587_CR122","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/sim.7635","volume":"37","author":"RK Silverman","year":"2018","unstructured":"Silverman RK, Ivanova A, Fine J (2018) Sequential parallel comparison design with binary and time-to-event outcomes. Stat Med 37(9):1454\u20131466. https:\/\/doi.org\/10.1002\/sim.7635","journal-title":"Stat Med"},{"issue":"1\u20133","key":"1587_CR123","first-page":"60","volume":"19","author":"EA Smith","year":"2022","unstructured":"Smith EA, Horan WP, Demolle D, Schueler P, Fu DJ, Anderson AE, Geraci J, Butlen-Ducuing F, Link J, Khin NA, Morlock R, Alphs LD (2022) Using Artificial Intelligence-based Methods to Address the Placebo Response in Clinical Trials. Innov Clin Neurosci 19(1\u20133):60\u201370","journal-title":"Innov Clin Neurosci"},{"issue":"7671","key":"1587_CR124","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nature23474","volume":"549","author":"J Biamonte","year":"2017","unstructured":"Biamonte J, Bergholm V, Christensen A, Schuld M (2017) Quantum machine learning. Nature 549(7671):195\u2013202. https:\/\/doi.org\/10.1038\/nature23474","journal-title":"Nature"},{"key":"1587_CR125","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12874-020-01124-6","volume":"20","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Ni W (2020) Performance of unanchored matching-adjusted indirect comparison (MAIC) for the evidence synthesis of single-arm trials with time-to-event outcomes. BMC Med Res Methodol 20:241. https:\/\/doi.org\/10.1186\/s12874-020-01124-6","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"1587_CR126","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1089\/cap.2019.0022","volume":"29","author":"Y Li","year":"2019","unstructured":"Li Y, Huang J, He Y, Yang J, Lv Y, Liu H, Liang L, Li H, Zheng Q, Li L (2019) The Impact of Placebo Response Rates on Clinical Trial Outcome: A Systematic Review and Meta-Analysis of Antidepressants in Children and Adolescents with Major Depressive Disorder. J Child Adolesc Psychopharmacol 29(9):712\u2013720. https:\/\/doi.org\/10.1089\/cap.2019.0022","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"1587_CR127","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1541-0420.2008.01004_1.x","volume":"64","author":"P Bacchetti","year":"2008","unstructured":"Bacchetti P, McCulloch CE, Segal MR (2008) Simple, defensible sample sizes based on cost efficiency. Biometrics 64(2):577\u2013585. https:\/\/doi.org\/10.1111\/j.1541-0420.2008.01004_1.x. (discussion 586-594)","journal-title":"Biometrics"},{"issue":"9","key":"1587_CR128","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1177\/0883073813495959","volume":"28","author":"EF Augustine","year":"2013","unstructured":"Augustine EF, Adams HR, Mink JW (2013) Clinical trials in rare disease: challenges and opportunities. J Child Neurol 28(9):1142\u20131150. https:\/\/doi.org\/10.1177\/0883073813495959","journal-title":"J Child Neurol"},{"key":"1587_CR129","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/prbm.S75670","volume":"8","author":"M Bystad","year":"2015","unstructured":"Bystad M, Bystad C, Wynn R (2015) How can placebo effects best be applied in clinical practice? A narrative review. Psychol Res Behav Manag 8:41\u201345. https:\/\/doi.org\/10.2147\/prbm.S75670","journal-title":"Psychol Res Behav Manag"},{"issue":"1","key":"1587_CR130","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1086\/JCE200819109","volume":"19","author":"NA Bostick","year":"2008","unstructured":"Bostick NA, Sade R, Levine MA, Stewart D (2008) Placebo use in clinical practice: report of the American Medical Association Council on Ethical and Judicial Affairs. J Clin Ethics 19(1):58","journal-title":"J Clin Ethics"},{"key":"1587_CR131","doi-asserted-by":"crossref","unstructured":"Benedetti F, Amanzio M (2011) The placebo response: how words and rituals change the patient\u2019s brain. Patient Educ Couns 84(3):413\u2013419","DOI":"10.1016\/j.pec.2011.04.034"},{"issue":"1572","key":"1587_CR132","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1098\/rstb.2010.0385","volume":"366","author":"TJ Kaptchuk","year":"2011","unstructured":"Kaptchuk TJ (2011) Placebo studies and ritual theory: a comparative analysis of Navajo, acupuncture and biomedical healing. Philos Trans R Soc B Biol Sci 366(1572):1849\u20131858","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"1587_CR133","doi-asserted-by":"publisher","unstructured":"Feldman AM (2013) Publishing \u201cInvisible\u201d and \u201cAbandoned\u201d clinical trials: a commitment for CTS. Clin Transl Sci 6(4):251\u2013253. https:\/\/doi.org\/10.1111\/cts.12087","DOI":"10.1111\/cts.12087"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01587-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01587-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01587-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T09:02:56Z","timestamp":1684227776000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01587-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":133,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1587"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01587-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2460023\/v1","asserted-by":"object"}]},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"assertion":[{"value":"9 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S. J. Tepper reports grants for research (no personal compensation) from Allergan\/Abbvie, Amgen, Eli Lilly, Lundbeck, Neurolief, Novartis, Satsuma, and Zosano; consultant and\/or advisory Boards (honoraria) from Aeon, Allergan\/Abbvie, Alphasights, Amgen, Aruene, Atheneum, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, ClearView Healthcare Partners, CoolTech, CRG, Currax, Decision Resources, Defined Health, DRG, Eli Lilly, ExpertConnect, FCB Health, Fenix, GLG, Guidepoint Global, Health Advances, Health Science Communications, HMP Communications, Impel, InteractiveForums, Keyquest, Krog and Partners, Lundbeck, M3 Global Research, Magnolia Innovation, MJH Holdings, Neurolief, Novartis, <i>P<\/i> Value Communications, Pain Insights, Inc, Palion Medical, Pulmatrix, Putnam Associates, SAI MedPartners, Satsuma, Slingshot Insights, Spherix Global Insights, Strategy Inc, System Analytic, Taylor and Francis, Teva, Theranica, Tremeau, Trinity Partners, Unity HA, XOC, and Zosano, salary from Dartmouth-Hitchcock Medical Center and Thomas Jefferson University, and.Continuing Medical Education (CME) honoraria from American Academy of Neurology, American Headache Society, Annenberg Center for Health Sciences, Catamount Medical Education, Diamond Headache Clinic, Forefront Collaborative, Haymarket Medical Education, Medical Education Speakers Network, Medical Learning Institute Peerview, Migraine Association of Ireland, Miller Medical Education, National Association for Continuing Education, North American Center for\u00a0CME, The Ohio State University, Physicians\u2019 Education Resource, PlatformQ Education, Primed, Texas Neurological Society, Vindico Medical Education, and WebMD\/Medscape.G. L\u2019Italien, is an employee and shareholder of Biohaven Pharmaceuticals.J. Cirillo, E. Kim, and J. M.\u00a0Tweedie were employees and shareholders of Biohaven Pharmaceuticals at the time of study and manuscript completion. J. Cirillo and J.\u00a0M. Tweedie are now employees of Pfizer.K. Lodaya, F. Pathan, and N. Antaki are employees of Boston Strategic Partners, Inc., which received funding to support the analysis and manuscript development from Biohaven Pharmaceuticals, which was acquired by Pfizer in October 2022.D. Riley was an employee of Boston Strategic Partners, Inc. at the time of this study.B. H. Nathanson\u2019s company (OptiStatim, LLC) received a consulting fee for data analysis from Boston Strategic Partners, Inc.P. McAllister reports research support from Abbvie, Amgen, Biohaven, Lilly, Lundbeck and Teva, consultant\/advisory boards for Abbvie, Biohaven, Impel, BDSI, ANI, Lilly, Teva and Lundbeck.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}